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The objective of this study was to assess efﬁcacy and safety of percutaneous ultrasound (US) guided
preferential radiofrequency ablation (PRFA) in early breast carcinoma under local anesthesia and to
evaluate a new assessment protocol. Eighteen breast cancer patients were enrolled in order to receive
PRFA treatment three weeks prior to resection. Pain assessment was performed using the visual analoge
scale. Analysis of treatment success was performed using magnetic resonance imaging (MRI) as well as
histological assays for hematoxylin & eosin (H&E) and cytokeratine 8 (CK8). In a subset of patients
contrast enhanced ultrasound (CEUS) was performed before and after treatment. MRI showed no re-
sidual tumor growth in 100% (18/18) of cases. Complete tumor devitalization was indicated in 83% (15/
18) of patients as judged by H&E staining and in 89% (16/18) as judged by immunostaining for CK8. In
100% (18/18) at least one histologic method showed devitalization in the entire tumor. Treatment was
well tolerated. Pain experienced during the procedure was mild. US-guided PRFA of small breast carci-
noma is feasible under local anesthesia. MRI and CK8 have proven valuable additions to the RF breast
tumor ablation protocol. CEUS shows potential as a modality for radiological follow-up.
 2013 The Authors. Published by Elsevier Ltd. Open access under CC BY license.Introduction less invasive treatment regimes. Lumpectomy followed by radiationGlobally an estimated 1.64 million women were diagnosed with
breast cancer in 2010 with incidence increasing most markedly in
developing countries resulting from a change in lifestyle conditions,
reproductive patterns, increasing average age and use of hormone
replacement. While mortality is comparatively high in developing
countries it remains constant or is falling in developed countries due
to advances in medication and radiotherapy as well as tumor detec-
tion in earlier stages as a result of screening programs. In Sweden,
which was one of the ﬁrst countries to implement a national
screening program in 1986, the median tumor size in breast cancer
patients diagnosed 2011was 17mm. There is a general trend towardsMedicine and Surgery, Kar-
4, 181 32 Lidingö, Sweden.
Schässburger).
r Ltd. Open access under CC BY licenstherapy is the preferred surgical treatment in women with unifocal
breast cancer if the procedure is expected to yield a cosmetically
acceptable result. Sentinel lymph node biopsy has replaced axillary
node clearance as the gold standard for staging of the axilla. In the
wakeof thisdevelopment,minimally-invasive technologies forbreast
cancer treatment have been studied using several different ap-
proaches. Radiofrequency ablation (RFA) seems to be the most
promising technology given its constantly high success rates, short
treatment time, low complication rates [1] and preferential destruc-
tion of tumor tissue as compared to surrounding fatty tissue [2].
However, several issues remain to be addressed before the
modality can expect widespread acceptance. Histological assess-
ment of RF treatment success is problematic. Standard H&E staining
proves unreliable when assessing RF treatment success [3], gener-
ally underestimating RF damage when performed shortly after
treatment [4,5]. Mammography and US are unsuitable to radio-
logically evaluate treatment outcome [6,7]. Futhermore, while
there is ample data on treatment under general anesthesia, expe-
rience is limited concerning treatment under local anesthesia in ane.
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electrode is crucial [8] there are currently no means available to
facilitate the cumbersome process of manual large diameter elec-
trode placement. Based on initial institutional experience in the use
of PRFA in breast cancer patients [2,9] the goal of this study was to
move the treatment into an outpatient setting and tackle the
identiﬁed shortcomings. The radiological protocol for patient se-
lection and treatment follow-up was improved by including MRI
and CEUS. Histological assessment was performed using CK8
immunohistochemistry as well as H&E and means for power-
assisted precision placement were introduced to aid the place-
ment of the treatment electrode.
Materials and methods
Patients
Patients included in our study had to be diagnosed with a uni-
focal, clearly distinguishable tumor with a maximum diameter of
16 mm as assessed by mammography, US and MRI. Exclusion
criteria included multifocality, diffuse growth patterns, tumors
with surrounding ductal carcinoma in situ (DCIS) and lobular can-
cer. In line with ongoing clinical trials on minimally-invasive abla-
tion technologies at the time (e.g. trial NCT00723294) the inclusion
criteria were altered during the course of the study to enable the
inclusion of patients with tumors that were ER/PR negative, Her2/
neu positive, of Elston grade 3, had a size of 2 cm and showed
25% of intraductal components. The study was approved by the
Regional Ethics Committee of Stockholm, Sweden (Ref. nr. 2008/
1018-31/3; 2010/963-32) and all procedures were performed in
accordance with the ethical standards of the World Medical Asso-
ciation (Declaration of Helsinki). If the patient fulﬁlled the inclusion
criteria, detailed written information about the study was given. If
the patient agreed, a written consent was obtained. Core biopsy
samples prior to PRFA treatment were retrieved and analyzed
regarding histological type, Elston grade and receptor status (es-
trogen receptor, progesterone receptor, Her2/neu, Ki67 and CK8).
RF treatment instrumentation
Radio frequency heating can be utilized to act preferentially
in breast cancer tumors, heating tumor strands relatively more
than surrounding non-tumor tissue [2]. It is therefore named
preferential radiofrequency ablation (PRFA). Successively devel-
oped prototypes (NeoDynamics AB, Sweden) incorporating an
internally cooled electrode design were used. The instrumenta-
tion is approved by the Medical Products Agency, Uppsala,
Sweden (Ref. code 561:2010/503820) for the purpose of this
study and conforms to the international safety norm EN 60601-1.
In a previous study at our institution it was reported that the
insertion procedure of the needle was problematic in certain
cases due to a hard consistency of the tumor in comparison to
the surrounding soft fatty tissue [9]. Since correct placement of
the treatment electrode is crucial for optimal treatment, a
handheld driver unit for power-assisted insertion of the elec-
trode as well as a specially designed treatment electrode was
developed. The driver unit aids the operator by delivering trig-
gered mechanical pulses thrusting the needle forward over a
controlled millimeter distance when encountering hard to
penetrate tissue.
Imaging modalities
For MR imaging a 1.5 T (Signa HDxt, GE Healthcare, USA) system
was used in combination with an intravenous gadolinium contrastagent (ProHance, Bracco Diagnostics, Italy). Ultrasonographic (US)
imaging was performed with an iU22 ultrasound device (Philips,
Netherlands) together with transducer L17-5 (17-5 MHz frequency
range) for common US and L9-3 (9e3 MHz frequency range) for
contrast-enhanced ultrasound (CEUS). The latter involved an
intravenous administration of sulfur hexaﬂuoride microbubbles
with a size of 1e10 mm (Sonovue, Bracco Diagnostics, Italy).
Treatment protocol
The ﬁrst four cases were treated in the operating theatre at the
department of surgery. Treatment was performed under local
anesthesia with means for administration of additional sedation/
analgesia available. In the inpatient setting patients routinely
received 1 g paracetamol and 25 mg meclozine before thermal
ablation. Upon discharge patients received 5 mg oxycodone and
500 mg paracetamol according to routine department protocol.
Subsequent 14 patients were treated in an outpatient setting at the
department of mammography. 40e75ml of mepivacaine (5 mg/ml)
and bupivacaine (2.5 mg/ml) combined with 5 mg/ml epinephrine
were injected at the insertion site as well as adjacent to the tumor
for pain control and to alienate the tumor from the skin and pec-
toral muscle. Tissue temperature was kept at 85 C for 10 min.
Electrical impedance was monitored in order to improve thermal
lesion control. To avoid thermal damage skin temperature was
monitored using a handheld 650 nm laser guided IR thermometer.
Ice was used for cooling. As suggested by several authors [8,9], the
electrode was routinely active upon retraction in order to prevent
possible seeding of disseminated tumor cells.
Pain assessment protocol
In order to quantify perceived pain resulting from PRFA treat-
ment under local anesthesia a measurement was performed using
the visual analoge scale (VAS, from 0 to 10; 0 ¼ no pain, 10 ¼ un-
bearable pain). Since the VAS is less useful for comparative analysis
across a group of individuals at one time point, but more suitable
for comparing events in a single individual, pain assessment was
performed at four different stages during the procedure. The pa-
tient was speciﬁcally asked to judge pain before treatment, during
administering of local anesthetics, during PRFA treatment and after
completion of the procedure. Furthermore, if there was any
discomfort whatsoever between the time of PRFA treatment and
surgery, it was noted.
Radiological and histological assessment
MRI was performed before and after PRFA treatment close to the
date of surgery. In a subset of six patients CEUS was performed
before and after PRFA treatment. PRFA treatment was carried out by
an experienced radiologist. Resected specimens underwent radi-
ography to evaluate extent and surgical margins. Subsequently
specimens were ﬁxed in 4% buffered formalin and cut into 3e4mm
slices. Sheaves containing the necrotic lesion were identiﬁed,
trimmed, parafﬁn embedded and processed into 4 mm sections. For
histopathological evaluation using H&E the sections were stained
following validated standard hospital protocol. For immunohisto-
chemical staining parafﬁn embedded sections were stained with a
monoclonal antibody to CK8 (35betaH11, VentanaMedical Systems,
Inc., Tucson, USA) using validated hospital standard protocol. A tris-
based buffer with a slightly basic pH (Cell Conditioning 1, Ventana
Medical Systems, Inc.) was used for pre-treatment. Sections were
subsequently counterstained with Hematoxylin II as well as Bluing
Reagent (Ventana Medical Systems, Inc.) and ﬁnally ﬁxated and
mounted. An automated Benchmark XT (Ventana Medical Systems,
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staining procedure. Radiologic and histopathologic assessment was
performed by an experienced specialist. In case of uncertainty, a
second experienced physician was consulted and agreement
achieved.
Statistical analysis
Given the low sample size, statistical evaluation of pain mea-
surements was aided by substituting missing values with median
values from each measurement stage. AWilcoxon Signed-Rank test
(alpha ¼ 0.05) was performed for comparing perceived pain during
administration of local anesthetics with pain during PRFA treat-
ment as well as pain before and after treatment.
Results
For characteristics of patients enrolled in this study see Table 1.
All patients except for one were scheduled for subsequent breast-
conserving surgery and sentinel lymph node biopsy (SLNB), radio-
therapyand systemic endocrine treatment.OnepatientwasplannedTable 1
Patient characteristics and treatment planning. Patients were considered ER/PR
positive if receptors were expressed in more than 10% of cells. None of the tumors
exhibited HER-2 gene ampliﬁcation as assessed by FISH (Fluorescence In Situ Hy-
bridization) analysis. BCT ¼ Breast conserving therapy, MT ¼ mastectomy,
RT ¼ Radiotherapy, ST ¼ Systemic therapy.
Frequency
(number)
Age (years) Median (range): 67 (46e84)
Menstrual status Postmenopausal 94% (17)
Premenopausal 6% (1)
Location in breast Left breast 39% (7)
Right breast 61% (11)
Tumor size MRI (mm) Median (range): 11 (5e20)
Tumor size US (mm) Median (range): 10 (6e15)
Tumor size mammo (mm) Median (range): 10 (6e15)
Tumor size pathology (mm) Median (range): 10 (5e16)
Lymph node stage Negative nodes 94% (17)
Positive node, 1 6% (1)
Malignancy grade Elston I 28% (5)
Elston II 72% (13)
Elston III 0% (0)
Tumor type Ductal 83% (15)
Ductal/Tubular 6% (1)
Tubular 11% (2)
ER Positive 100% (18)
Negative 0% (0)
PR Positive 89% (16)
Negative 11% (2)
Her-2 0 83% (15)
1þ 0% (0)
2þ 17% (3)
3þ 0% (0)
Ki67 (%) <10% 55% (10)
10e20% 33% (6)
20e30% 6% (1)
30e40% 6% (1)
>40% 0% (0)
CK8 Positive 94% (17)
Negative 0% (0)
N/a 6% (1)
Planned treatment BCT þ RT þ ST 94% (17)
MT þ ST 6% (1)to be treated with mastectomy without subsequent radiotherapy
since the tumor was located in the centre of a small breast.
After PRFA treatment, MRI showed no residual tumor growth in
100% (18/18) of cases. Complete devitalization of the tumor was
indicated in 83% (15/18) of patients as assessed by H&E staining and
in 89% (16/18) as assessed by immunostaining for CK8. Treatment
was performed in a median of 10 min (range 8e14) with post-
operative swelling wearing off after approximately 30 min. No
adverse eventswere reported. In the inpatient setting patients could
leave the hospital on the same day. In the outpatient setting patients
were able to leave after approximately one hour. Perceived pain
related to the procedure varied strongly. Taken together, pain
experienced during PRFA treatment can be considered mild with a
medianvalueon theVASof 2.5. Paindidnot differ signiﬁcantlywhen
comparing injection of local anesthetic and thermal ablation of the
tumor with median values of 2 and 2.5 respectively (n ¼ 18,
Z ¼ 0.656, p ¼ 0.512). The median value of pain reported by the
patient before and immediately after treatment was 0 and 0.5
respectivelywith the difference being signiﬁcant in this case (n¼ 18,
Z ¼ 2,032, p ¼ 0.042). Table 2 gives a detailed account of pain
management and assessment.
Judged by H&E staining most cases showed frank necrosis or
regressive changes compatible with devitalization of the entire
tumor and surroundingmesenchyme. In three patients this was not
the case. In patient nr. 3 the tumor was partially affected with ne-
crosis in surrounding fatty tissue including adjacent intraductal
cancer, but areas of the tumor had a viable appearance with no
signs of necrosis. Patient nr. 7 showed no signs of devitalization and
in patient nr. 18 the tumor was interpreted viable although certain
effects of treatment could be traced. However, when using CK8
staining no immunoreactivity was present. Fig. 1 illustrates CK8
immunostaining of a biopsy sample before and of the entire tumor
after treatment showing considerable distinction between viable
and non-viable epithelium. Using CK8 immunostaining the tumor
was interpreted as viable after treatment in two cases. In patient nr.
12 sparse staining was observed in areas throughout the tumor
illustrating a nonspeciﬁc CK8 staining in an otherwise clear-cut
regressive tumor (Fig. 2). In patient nr. 5 a slightly more distinct
staining was present in around 75% of the tumor (Fig. 3). In one
patient CK8 status before PRFA was not analyzed since not enough
tissue was present in the biopsy sample.
MRI was performed with a median of 13 days (range 6e21) after
PRFA treatment, shortly before resection, which was carried out
with amedian of 14.5 days after PRFA treatment (range 6e22). In all
cases the contrast enhancement in the target area had disappeared
indicating complete treatment response. An ablation cavity could
be seen surrounded by a peripheral ring as reported by other au-
thors [10]. In two patients the MRI procedure before PRFA treat-
ment lead to additional diagnostic investigations. In one of these an
MRI-guided biopsy was performed to assess a suspicious lesion and
in the other patient a contralateral diagnostic partial mastectomy
was performed due to suspicion of intracystic malignancy. In both
cases ﬁndings were benign. CEUS images before treatment were
heterogeneous, reﬂecting different vascularization patterns and
tissue properties of the tumor and surrounding tissue. After treat-
ment, CEUS images showed a clearly distinguishable ablation
margin (see Fig. 4). In all six cases when CEUS was used the radi-
ologist judged the ablation to be successful.
Discussion
Today, RFA is routinely used in cancer management. In the liver
it is a valuable curative treatment option for patients with unre-
sectable hepatocellular carcinoma and has gradually started to be
used to treat resectable tumors [11]. It has been included as an
Table 2
Comprehensive data concerning pain management and assessment. Pain assessment was performed prior to thermal ablation (A), during injection of local anesthetics (B),
during treatment (C) and shortly afterwards (D). MEP ¼ mepivacaine; BUP ¼ bupivacaine.
Nr. Local anesthetics Sedation Pain Assessment Comment
MEP [ml] BUP [ml] A B C D
1 e 40 No e e 2e5 0 3.75 mg/ml BUP solution was used. First half of the treatment VAS 2, second half VAS 5.
Patient reported temporary slight tenderness of the breast after treatment (max VAS 2).
2 e 40 Light e e 5e8 4 3.75 mg/ml BUP solution was used. During start of treatment VAS 6, subsequently
VAS 8 at which point 0.5 mg of alfentanil were administered. Pain level subsequently
decreased to VAS 5e6. Directly after treatment tensions in breast (max VAS 4). VAS 3
until two days after treatment.
3 20 40 No 1 e 7 1 No epinephrine due to patient request. Starting two days after treatment patient felt
discomfort in the treated breast (VAS 3).
4 20 40 Light e 1 0 0 Patient had chronically high blood pressure and stated she did not take her usual
medication (candesartan) before the intervention. Having a blood pressure of 180/100
we administered 30 mg of intravenous propofol. Patient reported no discomfort in the
time before surgery (VAS 1). Some itchiness of breast reported afterwards
5 20 40 No 1 e 1e2 1 VAS 1 up to eight minutes into treatment, subsequently VAS 2. Some tenderness
after treatment.
6 20 40 No 0 2e3 3e4 1e2 Patient experienced anxiety before the intervention and received 15 mg of intravenous
propofol.
7 20 20 No 0 1 0 0
8 20 45 No 1 4 3 1 Oxazepam before treatment.
9 20 20 No 1 1 1 1
10 20 35 No 0 4 2 0 Tenderness in breast after treatment (VAS 3)
11 20 35 No 0 1 1e5 0e3 Last two minutes of treatment VAS 5. During ﬁrst ten minutes after treatment VAS 3.
12 20 40 No e 4 3 0 Slight discomfort in breast after treatment (VAS 1e2)
13 20 35 No 0 2 1 0 Slight discomfort in breast after treatment (VAS 1e2)
14 20 30 No 0 1 1e5 3 Last minutes of treatment VAS 5. Tenderness of breast ﬁrst few weeks after treatment
(VAS 3)
15 20 30 No 0 2 0e1 0
16 35 40 No 0 7 9 1
17 20 30 No 0 5 0 0 Perceived temporary tachycardia after injection of anesthetics. Reasonably related to
the epinephrine. Itchiness after treatment
18 20 35 No 0 1 0 0
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patients with high surgical risk [12] and is available for high-risk
operable and medically inoperable lung cancer patients [13].
Furthermore, it is widely used in a both curative and palliative
setting for metastatic disease. Since the ﬁrst reported RFA treat-
ment in the breast in 1999 [14] numerous studies with different
treatment protocols, follow-up routines, imaging modalities, in-
clusion criteria and settings have been performed. RFA performed
under local anesthesia was ﬁrst reported by Burak [15] with several
studies following [6,16e23]. Most of the studies used sedation in
addition to local anesthesia including the only one that reported
quantiﬁed data on perceived pain during the procedure [17]. Our
data suggest that treatment under local anesthesia is feasible with
only mild pain perceived by the patient.
For radiological assessment MRI was the most signiﬁcant
improvement introduced in RF treatment of the breast since its
inception. MRI has been proposed as a tool both for patientFig. 1. Patient nr. 8 is representative of the patient group that showed no CK8 staining after P
brown staining of the epithelial cytoskeleton expressing CK8. After PRFA treatment, the tum
close-up (C, magniﬁcation 10). (For interpretation of the references to colour in this ﬁgurselection, especially to exclude patients with extensive intraductal
carcinoma (EIC) [9], as well as a modality to evaluate therapeutic
effect [10,20] where it was reported to reliably predict histologic
ﬁndings [24]. None of the patients in our study showed EIC. How-
ever, in two patients MR imaging prior to PRFA treatment lead to
additional suspicious ﬁndings and related costly diagnostic in-
terventions. Both ﬁndings were false-positive. While MRI delivers
decent results in patient selection, the additional costs and patient
discomfort of this modality should not be underestimated.
Contrast-enhanced ultrasound could be an alternative. It is today a
recognized tool for evaluating the immediate treatment effect and
guidance for subsequent immediate re-treatment in the RF ablation
of lesions in the liver [25]. Our preliminary results concerning the
use of CEUS are promising with post-treatment images suitable for
depicting ablation margins.
Histopathologic judgment of treatment success remains a
challenge. A general problem of the widely used H&E staining is theRFA treatment. The biopsy before treatment (A, magniﬁcation 20) shows a distinctive
or lacks immunoreactivity in the entire tumor (B, magniﬁcation 0.3) as well as in a
e legend, the reader is referred to the web version of this article.)
Fig. 2. In patient nr. 12 the biopsy shows clear positivity for CK8 (A, magniﬁcation 4) prior to treatment. After treatment, a light brown staining can be seen throughout most of the
tumor (B, magniﬁcation 10). However, when looking at the H&E staining (C, magniﬁcation 10) it can be assessed that the tumor is completely devitalized with signiﬁcant changes
with hyaline degeneration and loss of nuclear chromatin pattern in the connective tissue and tumour epithelium illustrating an example of unspeciﬁc immunostaining of CK8. (For
interpretation of the references to colour in this ﬁgure legend, the reader is referred to the web version of this article.)
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specimen [26] and the underestimation of cell devitalization level
when used less than six month after ablation [5]. Enzyme histo-
chemical analysis of cell viability using nicotinamide adenine
dinucleotide (NADH)-diaphorase analysis was successfully per-
formed in several studies [1] but requires frozen tissue which is
scarcely available due to the advanced infrastructure necessary. It
has poor morphology compared to parafﬁn sections and does not
work well for fatty tissues like breast, since fat hampers the cutting
of frozen sections [5,27]. It has recently been shown that the ability
to assess cell viability using immunostaining for CK8 in parafﬁn
embedded section is comparable to NADH-diaphorase staining in
frozen ones [27]. Two studies have previously used CK8 immuno-
histochemistry to determine cell viability after RFA in the breast
with good results [8,15]. CK8 immunostaining showed promising
results in our study and could be an alternative to the more costly
and cumbersome NADH-diaphorase staining assay. Since a small
percentage of breast tumors are stated to be CK8 negative [28] coreFig. 3. In patient nr. 5 a marked CK8 staining can be observed in the biopsy taken before PRF
the tumor as can be seen in the image showing the complete tumor (B, magniﬁcation 0.3)
the biopsy before treatment and signs of coagulation can be observed in the area. When com
(E, magniﬁcation 40) it can clearly be stated that morphological properties in both epithel
seems to be disproportionally unaffected as can be noted by morphologically viable fat cells s
references to colour in this ﬁgure legend, the reader is referred to the web version of thisneedle biopsy samples must be analyzed for CK8 positivity before
ablation.
In our opinion, three independent methods should establish
reasonable certainty concerning tumor tissue denaturation.
Radiologic imaging using MRI or CEUS is used for depicting the
physical boundaries of the ablated region. Images and/or video clips
before ablation should be stored to enable exact comparison. His-
tologic methods using H&E staining are used for judging
morphology and ﬁnally CK8 immunostaining for assessing cell
viability. Given their respective advantages, we suggest to focus
further research on CK8 immunochemistry and CEUS for histolog-
ical and radiologic follow-up respectively, since they leverage the
advantages of a minimally-invasive modality with respect to
increased patient comfort and cost-efﬁciency. A high level of ac-
curacy is required to insert and properly position the treatment
electrode inside the tumor [8]. Inprecise positioning can lead to
failed treatment procedures [9,24]. To date, the power-assistance
device was introduced into the protocol for the last two patientsA treatment (A, magniﬁcation 4). After treatment, staining persists in certain areas of
as well as in a close-up (C, magniﬁcation 10). However, staining is less distinct than in
paring the slides using H&E staining before (D, magniﬁcation 40) and after treatment
ial and connective tissue indicate denaturation. As previously discussed, adipose tissue
urrounded by denaturated cancer cells (F, magniﬁcation 20). (For interpretation of the
article.)
Fig. 4. Diagnostic images of patient nr. 15 using CEUS. CEUS images are shown on the left side while standard US images are displayed on the right respectively. These images are
taken before PRFA treatment (A) and 12 days afterwards (B). While CEUS overestimates tumor size before treatment, most likely due to vascularization around the tumor mass, it
depicts a marked and clearly visible ablation margin after treatment.
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results. However, evidence from these two cases points towards an
improved operator control over the introduction process and
optimal positioning of the electrode. Further studies using this
technology will yield decisive data.
As development progresses and evidence of efﬁcacy increases,
e.g. through randomized control trials, radiofrequency ablation has
the potential to become a tool for the treatment of small breast
carcinoma. As has been the case in liver and kidney lesions, prior to
minimally-invasive ablation treatments having matured, patients
with high surgical risk or those refusing surgical treatment could
initially beneﬁt from this treatment modality. Around 14% of breast
cancer patients in Sweden are over the age of 80. This patient group
poses speciﬁc challenges concerning surgery and hospitalization.
They more often belong to risk groups concerning general anes-
thesia, aremore cost-intensive due to co-morbidity, at a greater risk
of acquiring infections, stay hospitalized longer and run the risk of
mental confusion and depression due to loss of their home envi-
ronment. A pilot study in this patient population is currently
ongoing at our institution.
Conclusion
PRFA has the potential to be a safe and effectivemodality to treat
early breast carcinoma. It can be performed under local anesthesia
with minimal discomfort for the patient followed by discharge
within 60 min. MRI, CEUS and CK8 immunostaining prove suitable
additions to the protocol for patient selection and treatment
assessment. An adequately powered randomized control trial
comparing PRFA to routine breast conserving surgery with an
appropriate follow-up period is necessary to provide sound evi-
dence on local recurrence rate and side effects. PRFA could be a
valuable modality for the treatment of patients with contraindica-
tions to surgery or those refusing a surgical resection of the tumor.
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